Last quarter (Q4 2022), Lytix Biopharma AS's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q4, Lytix Biopharma AS's net income was kr-29.19M. See Lytix Biopharma AS’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	kr 1.41M	kr 1.41M	kr 17.00K	kr 3.00K	kr 310.00K
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	kr 67.86M	kr 67.11M	kr 48.03M	kr 42.38M	kr 33.27M
Operating Income	kr -66.45M	kr -65.70M	kr -48.02M	kr -42.37M	kr -32.96M
Net Non Operating Interest Income Expense	kr 1.97M	kr 1.97M	kr 141.00K	kr 355.00K	kr 805.00K
Other Income Expense	-	-	-	-	-
Pretax Income	kr -56.76M	kr -56.01M	kr -48.05M	kr -42.09M	kr -32.41M
Tax Provision	-	kr 0.00	kr 0.00	kr 0.00	kr 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	kr -56.76M	kr -56.01M	kr -48.05M	kr -42.09M	kr -32.41M
Basic EPS	kr -1.43	kr -1.40	kr -1.24	kr -1.09	kr -0.84
Diluted EPS	kr -1.43	kr -1.40	kr -1.24	kr -1.09	kr -0.84
Basic Average Shares	kr 160.27M	kr 40.07M	kr 38.74M	kr 38.74M	kr 38.74M
Diluted Average Shares	kr 160.27M	kr 40.07M	kr 38.74M	kr 38.74M	kr 38.74M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	kr 67.86M	kr 67.11M	kr 48.03M	kr 42.38M	kr 33.27M
Net Income From Continuing And Discontinued Operation	kr -56.76M	kr -56.01M	kr -48.05M	kr -42.09M	kr -32.41M
Normalized Income	kr -56.76M	kr -56.01M	kr -48.05M	kr -42.09M	kr -32.41M
Interest Expense	-	kr 55.00K	kr 3.00K	kr 0.00	-
EBIT	kr -56.70M	kr -55.95M	kr -48.05M	kr -42.09M	kr -32.96M
EBITDA	kr -56.67M	kr -55.92M	kr -48.05M	kr -42.09M	kr -32.96M

Currency in NOK

Lytix Biopharma AS Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing